Information Provided By:
Fly News Breaks for May 20, 2015
BMRN
May 20, 2015 | 07:17 EDT
Jefferies analyst Eun Yang sees greater than 25% upside in shares of BioMarin should the FDA approve drisapersen for Duchenne muscular dystrophy. After hosting an investor dinner with management, Yang says BioMarin's confidence in drisapersen approvability has increased. The analyst's model, which includes a price target for shares of $135 and a Buy rating, assumes 60% probability of approval for drisapersen. Shares of BioMarin closed yesterday down $1.03 to $124.99.
News For BMRN From the Last 2 Days
There are no results for your query BMRN